StrateGIST 3
StrateGIST 3: IDRX-42 vs. Sunitinib in patients with metastatic or unresectable GIST, after first-line Imatinib treatment.
| Agent: | IDRX-42 Sunitinib |
| Phase | III |
| Status | Recruiting |
| Sponsor | GlaxoSmithKline |
For further information please consult https://clinicaltrials.gov/study/NCT07218926
The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib.
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3).
WHO is the trial for? |
Additional medical eligibility criteria apply and are reviewed by the study team |
WHAT is the key question that this trial is attempting to answer? |
Is IDRX-42 effective and safe in treating adults with GIST when compared to sunitinib, after first-line treatment with imatinib? |
WHY patients might want to participate? |
This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in sarcomas and potentially help other patients with this disease.
The trial might or might not have benefit in your individual case. |
WHEN will the trial be open? |
This study is open for recruitment. |
WHERE is the trial available? |
The trial is being conducted in the US, Canada, Japan, Taiwan, United Kingdom.
For further information check here. US contact :
Name: US GSK Clinical Trials Call Center EU contact: Name: EU GSK Clinical Trials Call Center |
STUDY DESIGN: What does the study look like? |
Open label design.
Patients in Group A receive IDRX-42 (orally) |
HOW do I get more information? |
Patient organisations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving sarcoma patients.
If there are no such organisation in your country, please email us for more information: info@sarcoma-patients.org |
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.